Three studies of Kardia Mobile suggest accuracy, ease-of-use
by Greg Von Portz September 12, 2017

AliveCor recently announced results from several independent studies that showed how one of their flagship products, Kardia Mobile, may improve outcomes for patients with atrial fibrillation.
Kardia works by wirelessly connecting a pulse-monitoring pad to a smartphone, tablet, and wearables allowing patients to perform a self-administered EKG test almost anywhere. The results are displayed live on the screen and are very accurate, according to the studies, which were presented at this year’s European Society of Cardiology meeting in Barcelona.
One study from the Cleveland Clinic showed that Kardia’s accuracy was similar to that of a physician making the diagnosis. It also found that Kardia lessened anxiety associated with a diagnosis of Afib.
In a large study of more than 12,000 participants, a team at the Chinese University of Hong Kong found that Kardia’s 30-second EKG was able to correctly identify previously undiagnosed Afib patients — and a second team in Hong Kong from Princess Margaret Hospital was able to replicate those results. And evaluating a group of more than 10,000 non-medical professionals, the teams concluded that Kardia was easy to use.
The iMedicalApps team has previously reviewed consumer wearables that let patients do EKGs from the comfort of their own homes, but AliveCor now claims that Kardia is the most “clinically-validated EKG solution on the market.”

This article originally appeared on